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Abstract
Malaria mosquito research in Africa as elsewhere is just over a century old. Early trials for development of mosquito
control tools were driven by colonial enterprises and war efforts; they were, therefore, tested in military or colonial
settings. The failure of those tools and environmental concerns, coupled with the desperate need for integrated
malaria control strategies, has necessitated the development of new malaria mosquito control tools, which are to
be tested on humans, their environment and mosquito habitats. Ethical concerns start with phase 2 trials, which
pose limited ethical dilemmas. Phase 3 trials, which are undertaken on vulnerable civilian populations, pose ethical
dilemmas ranging from individual to community concerns. It is argued that such trials must abide by established
ethical principles especially safety, which is mainly enshrined in the principle of non-maleficence. As there is total
lack of experience with many of the promising candidate tools (eg genetically modified mosquitoes, entomopatho-
genic fungi, and biocontrol agents), great caution must be exercised before they are introduced in the field. Since
malaria vector trials, especially phase 3 are intrusive and in large populations, individual and community respect is
mandatory, and must give great priority to community engagement. It is concluded that new tools must be safe,
beneficial, efficacious, effective, and acceptable to large populations in the short and long-term, and that research
benefits should be equitably distributed to all who bear the brunt of the research burdens. It is further concluded
that individual and institutional capacity strengthening should be provided, in order to undertake essential
research, carry out scientific and ethical review, and establish competent regulatory frameworks.
Background
Without any doubt, malaria, a mosquito-borne disease,
is a leading cause of morbidity and mortality in Africa,
where it causes an estimated 300 million cases per
annum, and around one million deaths, mainly of young
children [1]. For sub-Saharan Africa (SSA), malaria is a
cause as well as a consequence of poverty, costing SSA
over US$12 billion per annum [2]. Overreliance on
using only anti-malarial drugs has over the years led to
successive resistance and subsequent loss of first-line
drugs. Mosquito vector control is, therefore, needed in
integrated malaria control, prevention and elimination,
without which malaria parasite resistance to anti-malar-
ial drugs would continue unabated [3].
Since existing vector control tools are turning blunt,
and are few, biomedical research is being intensified in
order to develop new mosquito vector control tools,
which must be tested on humans, in the human envir-
onment, or on fabrics used by humans. Such interac-
tions with humans at the individual, community and
country levels and with the environment are likely to
lead to ethical, safety, legal, regulatory, cultural, social
and other concerns. There is also concern that entomol-
ogy researchers do not usually consider ethical aspects
of their research, while there is anecdotal evidence of
their limited participation in ongoing training in health
research ethics in Africa. This paper will focus on ethi-
cal concerns, with occasional allusions to some of the
other concerns, especially safety. The paper should be of
interest to researchers, sponsors and reviewers of mos-
quito research in Africa and beyond.Correspondence: wlkilama@amanet-trust.org
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Health research ethics is mainly guided by four broad
principles, namely, respect for a person’s autonomy, bene-
ficience, non-maleficence and justice. For a concise
description of these terms the interested reader should
refer to the Declaration of Helsinki [4], and introductions
to the guidance documents of the Council for Interna-
tional Organizations of Medical Sciences [5,6]; these gui-
dance documents will be frequently referred to in this
paper. For a more detailed discourse from an African per-
spective, readers may consult the paper by Tangwa [7].
Although human attempts at reducing mosquito bites
are as old as human history, mosquito control strategies
derived from research findings is only about a century
old. In Africa, mosquito control tools were initially
mainly developed during the early colonial period to
safeguard colonized urban areas, mines and agricultural
estates. Intensive efforts were invested in the research
and development of malaria control tools during World
War II, which resulted in the production and introduc-
tion of chloroquine and DDT [8], that later became the
leading anti-malarial arsenal in the global malaria eradi-
cation programme of the 1950s and 1960s. It is also
claimed [9] that insecticide-treated nets (ITNs) were
initially developed for military use. Consequently, trials
in the development of these insecticidal chemicals were
initially undertaken in military facilities, on military per-
sonnel and later deployed on colonial agricultural
estates, mines, and urban areas, which were the major
beneficiaries. It is only recently that insecticidal pro-
ducts, particularly ITNs, have been specifically devel-
oped for majority civilian use in African populations.
This demands a paradigm shift in the process of
developing products for malaria mosquito control.
Whereas previously products were intended to protect
individual short-term travelers, such as military person-
nel, colonial administrators, itinerant traders and tour-
ists, the involvement of large, vulnerable, resident,
civilian populations sets new demands in product devel-
opment. In malaria mosquito control trials to be under-
taken in Africa, the investigators, sponsors and
reviewers of trial protocols must, therefore, be mindful
of individual, community and environmental protec-
tions; equitable access to and sharing of benefits from
research; and, given African realities, they should also
address capacity strengthening not only of researchers,
as is the case in clinical trials, but also of trial commu-
nities and institutions to be involved in the trials.
Unlike clinical trials, vector control trials will of neces-
sity involve population-wide testing, which may infringe
on individual freedoms, but can result in significant ben-
efits for populations.
This paper will attempt to illustrate the ethical and
practical concerns with available and candidate vector
control strategies, and make attempt at addressing them.
Epidemiological studies
Entomological studies are a crucially important compo-
nent of malaria epidemiological studies. Mosquitoes
must be collected in very early studies, so as to incrimi-
nate species responsible for malaria transmission, their
feeding, biting, resting and other habits, and their sus-
ceptibility to prospective control measures. The collec-
tion of female mosquitoes, which is often undertaken in
such studies, can be dangerous to mosquito collectors,
who are sometimes referred to as mosquito bait, and
some entomologists still prefer man-landing catches
[10]. Quite often mosquito collectors are poor people,
who undertake even the most demeaning tasks to
scratch a living; they may, therefore, be classified as vul-
nerable research participants. In such situations,
research staff are perpetrators of harms on fellow
researchers. Surely mosquito collectors, who constitute
an essential component of the research team must
be protected; as humans, their autonomy must be
respected. Indeed, their informed consent must
be obtained before a study starts, and mechanisms must
be put in place to ensure that the collectors understand
and continue to understand the hazards involved in
their participation.
Since in most cases mosquito collectors are employees
of the research team, and are paid wages, some
researchers argue against the requirement for informed
consent. In all probability, the collectors got enrolled
against their autonomy; because of poverty they cannot
make a free choice. Moreover, it is very rare that senior
researchers will offer themselves to undertake this or
similar tasks, knowing the inherent harms relating to
mosquito bites and the probability of transmitting
malaria, filariae, and arboviruses, that are often endemic
in study communities. Such involvement falls under the
principle of non-maleficence (do no harm). In some
situations, employment contracts create binding bon-
dages, by requiring some employees to enter employ-
ment contracts as mosquito collectors. This author is of
the opinion that even in such contracts informed con-
sent by mosquito collectors be required, and should be
periodically renewed. Information to be provided to a
mosquito collector before s/he participates in the collec-
tion should include that contained in CIOMS Guideline
5 [6], more specifically:
• why s/he is considered suitable for the role to be
played, and that participation is voluntary;
• the purpose, the procedures, duration, the recom-
pense to be provided, foreseeable risks, pain, discomfort
or inconvenience of the research;
• that the individual is free to refuse to participate and
will be free to withdraw from the research at any time
without penalty or loss of benefits to which s/he would
otherwise be entitled;
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• the expected benefits to the individual participant
and the community;
• the sponsors of the research, the institutional affilia-
tions of the investigators, and their funding;
• the extent of the investigator’s responsibility to pro-
vide services to the collector ;
• that treatment will be provided free of charge for
research related conditions including infections from
mosquito bites; and
• that an ethical review committee has approved or
cleared the research protocol.
Furthermore, all out efforts should be made to use
much safer mosquito collection methods, including light
traps, double net traps, and animal bait.
Existing vector control tools
Existing vector control tools include insecticidal chemi-
cals (eg organochlorides, pyrethroids, organophosphates,
and carbamates), biocontrol agents and environmental
modification strategies. Because all these pose various
risks to humans, and the mosquito habitats, from an
ethical perspective, there is need for specific protections
and restrictions. As a consequence, the safety of
research participants, whether individuals or commu-
nities, and that of the environment must be given fore-
most attention. In the latter regard, the DOH under
paragraph 13 requires that “Appropriate caution must
be exercised in the conduct of medical research that
may harm the environment”. For DDT, for example,
there are many claims of toxicity to birds, carcinogeni-
city, and being anti-androgenic [11]. Exhaustive litera-
ture on both sides of the debate has been provided [12].
DDT supporters, however, vehemently deny the claims;
they point to faulty study designs and interpretation,
reasoning that even if DDT is dangerous, the gains
made in saving so many human lives by far outweigh
the harms [13-16] These debates led to the adoption of
the Stockholm Convention on Persistent Organic Pollu-
tants [17], under which DDT was not banned if used in
accordance with WHO procedures. But later debates
unleashed the precautionary principle [18], which puts
the onus on those proposing the action to prove that
the action is harmless. A Lancet editorial [19] appealed
for “caution with the precautionary principle”; the latest
WHO [20] position was adopted in the light of the pre-
cautionary principle.
Moreover in some trials consideration must be given
to such aspects as dermal toxicity, corrosiveness to fab-
rics, and effects on treated surfaces. Indeed the “safe use
of pesticides” has for decades been a WHO concern,
especially as an occupational health hazard [21].
The adoption of a drug or vaccine for disease manage-
ment is invariably based on the efficacy of the candidate
product, which must be monitored to ensure continued
efficacy. Indeed the DOH [4] under para 7 states that ”
even the best current interventions must be evaluated
continually through research for their safety, effective-
ness, efficiency, acceptability and quality.” Similarly, with
mosquito control tools, especially so with insecticides,
efficacy must be established before the insecticide is
adopted for use [22], and must be monitored regularly,
particularly given the frequent threat of insecticide resis-
tance. Monitoring must, therefore, include not only
safety and efficacy but also continued assessment of
effectiveness, efficiency, acceptability and quality. Failure
to do so would be unethical as it would expose humans
to poisonous or inefficient, unacceptable, and low qual-
ity products whose value in operational programmes is
questionable.
The World Health Organization [23] has in place the
WHO Pesticide Evaluation Scheme (WHOPES), which
runs a four-phase evaluation and testing scheme, so as
to establish the safety, efficacy and operational accept-
ability of insecticides intended for use in public health,
and develops specifications for quality control and inter-
national trade. In particular, phase 1 tests for efficacy
and persistency of technical products or their formula-
tions using laboratory-bred arthropods; phase 2 studies
natural mosquito populations in the field, on a small
scale under well controlled conditions, and determining
likely harmful effects upon operators; products passing
phase 2 testing may get interim registration. Phase 3
assesses product efficacy under medium or large-scale
field trials, including epidemiological evaluation; pro-
ducts passing phase 3 testing get full WHOPES registra-
tion. Phase 4, on the other hand, establishes
specifications for the technical product [22]. Some Afri-
can research institutions, including the Amani Research
Centre and KCM College in Tanzania, CREC in Benin,
Kow Valley in Burkina Faso, Pitoa in Nortern Camer-
oon, Akodessewa in Togo, Malanville in North Benin,
participate as WHOPES testing sites for phase 2 and 3
trials.
In malaria control programmes, as exemplified in the
development of ITN strategies, entomological efficacy
must be followed by determining efficacy, for example,
on child morbidity and mortality. During the develop-
ment of ITN technology, some studies even determined
parasitological efficacy, whereby attempts were made at
determining reductions in parasite densities and fever
[24]. Indeed in malaria endemic settings, where poverty
is often rampant, feasibility, cost effectiveness, sustain-
ability, durability and impact of the tested strategy must
also be determined. From an ethical standpoint, when
studies are over, under DOH 2008 para 33 the partici-
pants “ are entitled to … share any benefits that result
from it, for example, access to interventions identified
as beneficial in the study or other appropriate care or
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benefit”. This requirement is also covered under guide-
line 10 of CIOMS 2008, which states in part that “any
intervention or product developed, or knowledge gener-
ated, will be made reasonably available for the benefit of
that population or community.” In the body of CIOMS
guideline 10, it is further stipulated that “if an investiga-
tional intervention has been shown to be beneficial, the
sponsor should continue to provide it to the subjects
after the conclusion of the study and pending its
approval by a drug regulatory authority, when relevant”.
It may be queried as to how long the sponsor’s obliga-
tion to provide the product should last and when it
should end, or whether it is open ended. Besides, unlike
in clinical trials, which are limited to individual research
participants, entomological intervention trials in phase 3
may be widespread and providing a successful product
to the entire study population may, therefore, be
deemed impractical. Furthermore, a successful trial may
demand building a new factory for manufacturing the
trial product, when due to endemic poverty the market
may be extremely weak, and the product unaffordable.
Candidate vector intervention tools
The dawn, intensification and threat of the spread of
insecticide resistance and environmental concerns have
encouraged efforts in the discovery, and development of
new mosquito vector control tools. These for example
include new synthetic insecticides [25], entomopatho-
genic fungi [26], mosquito behavioural alterations [27],
genetic control and genetic engineering. The latter is
appropriately covered by Yeya Toure [28] in a paper in
this issue. For an overall perspective of the field, the
reader is referred to Takken and Knols [29]. These pro-
spective vector control tools pose new challenges to
national and international regulatory frameworks before
their approvals for adoption in public health programs.
Challenges and ethical implications in vector
control trials
Phase 1 vector control research is entirely laboratory
based and does not usually pose substantial ethical chal-
lenges. There are however ethical concerns where mos-
quitoes are fed on humans, or on laboratory animals.
The ethics of the use of laboratory animals in African
settings has been recently reviewed [30]. Ethical dilem-
mas in phase 2 testing relate mainly to operators who
are exposed to the product under development. These
operators must be adequately protected. In phase 3
trials, test products are applied under medium or large
field scale including epidemiological evaluation, aiming
at protecting entire communities, which in some trials
can be in thousands or tens of thousands; there are
inherent complex ethical challenges which may be
extensive depending on the trial design.
As a consequence, in phase 3 vector control trials,
individual informed consent cannot suffice; the research
team is duty bound to obtain household, community,
ward, or district-wide consent, depending on the extent
of the spread of the intended intervention trial. The
consent process in such studies is mind-boggling. Surely,
community assent as currently used for example in
community engagement would not suffice, since in vec-
tor control trials, especially where live mosquitoes are
released, or in trials of aerial spraying, the entire com-
munity population constitutes research participants per
se. Faced with such unwieldy situations, it has been
argued by some ethicists that alternative means be
found, for example by having a referendum, plebiscites
or other democratic means, as a supplement to
informed consent. The applicability of such approaches
in community-wide malaria vector control trials in Afri-
can settings are however doubtful.
It has been argued [31-36] that some candidate vector
control technologies, in particular genetically modified
mosquitoes, raise questions relating to the likely transfer
of transgenes to non-target organisms, disturbing the
culicine habitat, and the competitiveness of transgenic
mosquitoes, thus again pleading for caution with these
new technologies.
Some of the above challenges have been addressed by,
for example, the introduction of contained (caged) field
trials. The pertinent Scientific Working Group [37] has
recommended:
• instituting security and safety oversight, through
monitoring, biosafety, and regulatory organs.
• independent external audit;
• developing and using SOPs for safe keeping and
transport,
• observing international covenants and protocols,
• observing national, regional, state or provincial,
country or municipal, or institutional regulations,
It is, however, doubtful whether such regulations exist
in prospective African countries intending to participate
in such trials, and whether they are capable of enforcing
them. Such regulations would for example cover:
• Release of organisms in the environment,
• General biosafety requirements,
• Research ethics and human participant requirements,
• Environmental health regulations,
• Occupational safety,
• Transportation regulations,
• Quarantine regulations, and regulations by funder
and/or sponsor,
It is most probable that most African countries lack
such regulations, and where they exist the regulatory
bodies are weak and cannot, therefore, appropriately
enforce them. Furthermore, at research institutional
level there is insufficient strength to, for example, clear
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importation of live organisms, undertake scientific or
ethical review [38], carry out monitoring or oversight.
Consideration should, therefore, be given to initiation of
supranational review mechanisms as is currently done
under EDCTP for drug and vaccine trials in Africa[39].
The capacity strengthening of such regulatory frame-
works must be given high priority.
Case studies in malaria mosquito trials and
control
Currently, insecticide-treated nets (ITNs) and long-last-
ing insecticidal nets (LLIN) are the mainstay of malaria
control across SSA. In some areas indoor residual spray-
ing is being implemented. LLIN deployment in commu-
nity-wide control programmes has resulted in drastic
malaria reductions, as has happened in Zanzibar, Eritrea,
Madagascar, Rwanda, Sao Tome and Principe, and Zam-
bia [1]. These phenomenal successes were preceded by a
number of ethical issues during product development,
as illustrated in the following case studies. (Fig.1 and 2).
Community engagement
Community engagement has recently become popular in
clinical trials and in epidemiological studies [45,46]. It is
now commonly agreed that before a community-based
study starts prospective study communities should be
provided with clear non-technical descriptions of the
intended study, including the thinking behind the study,
its objectives, and the activities to be undertaken, aimed
at obtaining community acceptance of the study. Since
entomological trials are by their very nature commu-
nity-based, and may be intrusive, community engage-
ment should play a much greater role.
The acceptance of a new technology or for that matter
accepting to participate in a study is not straight for-
ward, especially with entomological trials, which fre-
quently arouse suspicion and rumor-mongering [47-49].
In order to elicit community acceptance, it will be
necessary to use various approaches, including drama,
video, animation, and road shows. The study must be
explained clearly, including its rationale and justification,
any likely risks, their likely magnitude, and how to han-
dle them. It is absolutely essential that the study team
have an inbuilt mechanism to get feedback. Since
informed consent is a process, it should not be rushed
through; likely local concerns must be addressed
adequately.
It is advisable that the researchers know study com-
munities well; in this regard collaboration with social
scientists, especially sociologists should be given high
priority. Study teams should aim at building trust with
study communities, to secure and sustain community
endorsement and consent, establish means of communi-
cating with communities, and give communities a sense
of project ownership. Tindana[45], working in Ghana,
has described the Navrongo model of community
engagement, which starts with community entry, then
holding community Durbars, followed by compound
and household meetings, all leading to individual con-
sent. Such procedures would equally be quite appropri-
ate for other communities of SSA. What is abundantly
clear is that in community wide studies the need to
respect local behavior and etiquette is absolutely neces-
sary. In entomological intervention studies the process
would be more complex, and indeed it is not uncom-
mon in such trials to have house entry refusals or
research interventions confused with vector control
interventions, an equivalent of therapeutic misconcep-
tion in clinical trials. House entry refusals are not
uncommon, especially with affluent households, where
some may claim “not in my backyard”. Some successful
projects have involved community advisory boards or
community-owned resource persons [50]. But whatever
the case, sustaining consent and rumor management are
often difficult. During the study, all efforts should be
made to minimize having non-consenting individuals, as
they might wreck the entire project, since the entire
study population constitutes a cohort. Indeed obtaining
and sustaining informed consent throughout study com-
munities, which would necessarily involve thousands of
participants would be unwieldy. Even where consent is
obtained, it would be extremely difficult, if not impossi-
ble to ensure that the consent obtained in such large
trials is genuine, persists throughout the study popula-
tion and is sustainable.
Balancing benefits, harms and risks
Vector control strategies are a mixed bag in that they all
contain potential benefits, harms, and risks. It is upon all
stakeholders, encompassing researchers, sponsors, and
the scientific and ethics review committees to make sure
that in intended vector control trials there is a balancing
of potential benefits, risks and harms, which in this case
must also consider the community and the environment.
Study designs must be examined to make sure that pro-
spective intervention trials are at least as advantageous to
the community and the environment, in the light of
potential harms and benefits. Contingency plans must
always be put in place for mitigating such “adverse
events”, such as escape of GM mosquitoes, which may
have increased vectorial capacity or vector competence
for non-target pathogens, increase in mosquito fitness or
longevity, changed blood feeding habits, decreased insec-
ticide susceptibility, and horizontal gene transfer. It was
these types of concerns that led to the development of
contained field trial cages that are capable of minimizing
potential escape of live mosquitoes, entomopathogenic
fungi, and other exotic organisms. Even with such
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facilities security and safety oversight must be instituted,
including their monitoring, inspection by regulatory
organs, and independent external audits [37].
Strengthening capacity for scientific, ethical and
regulatory review
Before undertaking entomological studies, particularly
those involving humans, intended study protocols must
be examined by competent review committees for their
scientific merit and ethical acceptability. In most African
research institutions, scientific review precedes ethical
review. This approach is mainly based on the principle
that if the science is faulty, it may expose participants to
risk or inconvenience to no good purpose and, there-
fore, the study cannot be ethical. Subsequently, it should
be upon the scientific review committee to determine
whether a cleared protocol should undergo ethical
review. In case an entomological study claims that it is
exempt from review, the research protocol should con-
tain a statement to justify the claim. Nevertheless, such
a protocol should receive competent administrative
clearance that it is indeed exempt from review.
Such committees must be independent of the research
team, be competent, and multidisciplinary. Since in
most institutions medical entomologists may not be
members of the ethics review committee, they should at
least be co-opted on ad-hoc basis as need arises.
According to CIOMS [6] Guideline 20 “Many coun-
tries lack the capacity to assess or ensure the scientific
quality or ethical acceptability of epidemiological
research.” This dictum is very pertinent to malaria ento-
mological research, since senior malaria entomologists
are few and may not be members of either ethics or
scientific review committees.
Figure 1 DDT Case Study: Chronological Events
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Besides capacity for scientific and ethical review of
clinical and epidemiological research, countries and
institutions should also have in place capacity for regu-
latory review of entomological protocols, providing
monitoring and oversight of vector intervention trials,
which would contribute immensely to the facilitation
of national registration of new entomological interven-
tion tools. In Tanzania for example the Tanzania Food
and Drug Authority [51] does not undertake entomo-
logical review or oversight; this falls under Tanzania’s
Tropical Pesticides Research Institute (TPRI)[52].
Malaria mosquito control is a component of public
health, a very broad field encompassing many other
fields. Unfortunately, health research ethics focuses
attention on individual human protection, and as far as
this author is aware, there are no ethical guidelines for
public health research, including that on malaria mos-
quito trials. The development of such guidelines is
long overdue, and should be given the priority it
rightly deserves.
Fortunately, the WHO Special Programme for
Research and Training in Tropical Diseases (WHO/
TDR) is funding a project, designated MosqGuide,
which is developing the needed guidance for genetically
modified (GM) mosquitoes intended specifically to con-
trol malaria and dengue vectors. The guidance will sup-
port disease endemic countries and other stakeholders
in considering the safety and legal/regulatory aspects, as
well as ethical, cultural and social issues, of such deploy-
ment [53].
Figure 2 Comparison of two existing types of LLINs
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Conclusions
Although malaria mosquito research in Africa is over a
century old, it has hardly paid attention to ethical con-
cerns, although the development of mosquito control
tools must be tested on humans, on their fabrics, their
dwellings, or on the environment, and may cause harm.
In order to face the many ethical and practical chal-
lenges inherent in the research and development of new
malaria mosquito control tools, it is paramount before
studies start to provide comprehensive institutional
capacity strengthening based on entomological holistic
needs assessments. It should include strengthening ethi-
cal and regulatory review, developing ethical guidelines
for public health intervention trials, which should
include entomological aspects, while ensuring scientific
and ethical review of entomological studies, co-opting
entomological expertise as is deemed necessary. At the
same time institutional, national and international regu-
latory frameworks, including WHOPES should be
strengthened. New mosquito control tools must be
tested beyond safety and efficacy, to include also effec-
tiveness, acceptability, access, biosafety, and risk-benefit
considerations, not forgetting environmental and health
impact assessment. While undertaking trials ensure
involvement of majority of stakeholders, promote parti-
cipatory research and community engagement, and
minimize rumour mongering. Since mosquito control
trials are community-wide, aim at obtaining and sustain-
ing community consent even though it is much more
demanding than in typical cases of individual consent.
As there are many justice issues during trials, and many
more especially when trials are over, they must be ade-
quately addressed.
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